Macrocyclics, Inc., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine.
Providing tools and solutions in the field of nuclear medicine for site-specific bioconjugation, advanced chelating agent technology, and peptide intermediates.
Macrocyclics introduced its cGMP manufacturing services in 2005. Our quality system is designed specifically for the manufacture of APIs to be used in clinical trials.
Our team provides comprehensive technical support for all catalog products. We also offer custom synthesis, contract manufacturing, and project consultation tailored to specific needs.
At Macrocyclics, we listen to client requests and are excited to introduce new products in response to your ideas and suggestions.
Stay informed on new technology, partnerships, collaborations, and events.
Nov 01, 2016
Macrocyclics was contracted by Radiomedix and AREVA Med to produce the cGMP peptide conjugate that will b…Read More
Oct 27, 2016
Please visit the Macrocyclics team at our booth between June 10 & June 14…Read More
Oct 15, 2016
Visit Macrocyclics at Booth #96Read More
Apr 13, 2016
AREVA Med has launched operations at its second high-purity lead-212 (²¹²Pb) production facility located…Read More